Forecast

Buy	6
Hold	2
Sell	1

News Go to news feed

IMUNON presents new data on ovarian cancer therapy IMNN-001 at SITC

IMUNON will present translational data from the phase‑2 OVATION 2 study of IMNN-001 at the SITC meeting in early November; a poster by Douglas V. Faller examines the remodeling of the tumor microenvironment. OVATION 2 showed a median overall survival benefit of 13 months and a median progression‑free survival benefit of 3 months in the IMNN-001 treatment arm, with additional benefit from PARP inhibitor maintenance therapy. The company is advancing the registrational phase‑3 OVATION 3 trial, which includes two planned interim analyses of the primary endpoint and could speed an FDA submission if successful. Financially the situation is rated weak: IMUNON reported a Q2 EPS miss of -$2.15 versus -$0.32 expected and has a high cash burn rate. » More on de.investing.com
Imunon reports significant increase in quarterly loss

Imunon reported a loss per share of $32.25 for the quarter ended June 30, 2025, compared to a loss of $7.65 per share in the same quarter last year. This marks a substantial increase in the quarterly loss year over year. No further details on revenue or outlook were provided. » More on finanzen.net
Imunon misses Q2 2025 earnings forecast by a wide margin and shares plunge

Imunon significantly missed earnings expectations in the second quarter of 2025, reporting an EPS of -$2.15, which led to a nearly 10% drop in its share price. Despite progress in cost reduction and the advancement of the OVATION III Phase 3 trial, the company continues to face ongoing net losses and financial challenges. Management is exploring strategic financing options to regain NASDAQ compliance and support international expansion. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2008, IMUNON has already paid 1,15€ in dividends. The last payout was in April 2008.

Financials

In the last quarter, IMUNON had revenue of 0.00€ and net profit of −2.47b€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−2.47b	6,05%
EBITDA	−2.45b	21,23%

Fundamentals

Metric	Value
Market capitalization	+12.42m€
Number of shares	7.43m
Dividends	No
Beta	2,26
P/E ratio	−0,35
PEG ratio	0,00
P/B ratio	+1,99
P/S ratio	0,00

Company profile

Die Celsion Corporation, ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung von DNA-basierten Immuntherapien, Impfstoffen und gezielten Chemotherapien. Die Produktpipeline des Unternehmens umfasst GEN-1, eine DNA-basierte Immuntherapie für die lokale Behandlung von Eierstockkrebs, und ThermoDox, eine patentrechtlich geschützte hitzeaktivierte liposomale Verkapselung von Doxorubicin, die sich für verschiedene Krebsindikationen in der Entwicklungsphase befindet. Das Unternehmen verfügt außerdem über zwei Plattformtechnologien für die Entwicklung von Immuntherapien auf Nukleinsäurebasis, Impfstoffen und anderen DNA- oder RNA-Therapien gegen Krebs, die sich im Stadium der Machbarkeit befinden. Die Celsion Corporation wurde 1982 gegründet und hat ihren Sitz in Lawrenceville, New Jersey.